NBIX News and Press, Neurocrine Biosciences Inc. From 12/15/23

2023-12-15 14:30:49 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips As technology advances in our era, biotechnology is not far behind. Modern day medical advancements are impressive, and the company’s making these strides have incredible results to show...

2023-12-13 15:53:47 ET More on Neurocrine Biosciences Neurocrine Biosciences: Fear Not The IRA Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Neurocrine gets FDA...

2023-12-05 17:16:18 ET More on Neurocrine Biosciences Neurocrine Biosciences: Fear Not The IRA Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Neurocrine settles ...

Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia PR Newswire Company Today Also Provided Updates on R&D Portfolio and Strategy at Investor Event Crinec...

2023-12-01 10:17:15 ET The UBS pharma equity team is out with a quant list of most crowded stocks on the long and short side. Crowding is a sentiment metric that basically measure popularity in positioning (long or short). It indicates if a stock has a significantly above-average number...

Neurocrine Biosciences to Host Analyst Day on December 5, 2023 PR Newswire SAN DIEGO , Dec. 1, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company, will hold its Analyst Day focused on its R&a...

2023-11-30 12:16:34 ET Summary Neurocrine Biosciences' stock has been stagnant due to a lack of appreciation for positive updates and the modest mid-stage pipeline setbacks. The company recently settled with generic filers, ensuring no generic launch of Ingrezza until 2038 and hig...

2023-11-30 09:53:30 ET More on Neurocrine Biosciences Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success Neurocrine settles all patent disputes related to movement disorder therapy Neurocrine reports Phase 2 study failures for two...

2023-11-13 13:23:47 ET More on Neurocrine Biosciences Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To...

Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation PR Newswire SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company,...